How Long Should You Take Peptides?

For laboratory and research use only. Not for human consumption.

The Honest Answer: It Depends on the Peptide and the Goal

There is no single answer to “how long should you take peptides?” because peptides are not one thing. They are a broad category of compounds, each with different mechanisms, different goals, and different timelines. Asking how long to take peptides is like asking how long to take medicine — it depends entirely on which one and why.

Let’s break it down by category.

GLP-1 Peptides for Weight Management: Plan for the Long Term

This is the most important category to understand, because the answer might surprise you: GLP-1 peptides like semaglutide, tirzepatide, and retatrutide are designed for long-term use.

The major clinical trials ran for 48 to 104 weeks — that’s one to two full years. The STEP 5 trial followed semaglutide users for 104 weeks (two years) and found that weight loss continued to improve through the entire period (PMC9556320).

The Weight Regain Problem

Here’s the hard truth: when people stop GLP-1 peptides, most of the weight comes back.

The STEP 1 trial extension tracked what happened after participants stopped semaglutide at week 68. By week 120 — about one year after stopping — participants had regained two-thirds of the weight they had lost. The average person went from losing 17.3% of their body weight to keeping off just 5.6% (PMC9542252).

A broader meta-analysis confirmed this pattern across all GLP-1 drugs. The estimated weight regain after stopping semaglutide was about 9.9 kg (22 lbs) within the first year, with a projected return to baseline weight by approximately 1.5 years after stopping (PMC12535773).

A narrative review of randomized studies on weight regain after stopping liraglutide, semaglutide, and tirzepatide confirmed that discontinuation is consistently followed by significant weight regain (PMC12155999).

This doesn’t mean GLP-1 peptides don’t work. They work extremely well — while you’re using them. The issue is that obesity is increasingly understood as a chronic condition, not a temporary problem. Just as stopping blood pressure medication causes blood pressure to rise again, stopping weight management peptides allows weight to return.

The Maintenance Dose Concept

Many researchers and clinicians are moving toward a “maintenance dose” approach. The idea: use a full dose to reach your target weight, then reduce to a lower dose for long-term maintenance. This strategy was tested in the SURMOUNT-4 trial for tirzepatide, where participants who continued on the drug after initial weight loss maintained 89.5% of their results, while those switched to placebo regained most of their weight (PMC10714284).

The practical takeaway: if you start a GLP-1 peptide for weight management, plan for it to be a long-term commitment, not a short course.

BPC-157 for Injury and Gut Healing: 4-8 Week Cycles

BPC-157 is used very differently from GLP-1 peptides. It’s typically studied in targeted cycles aimed at a specific healing goal — a tendon injury, gut inflammation, or tissue repair.

Most research protocols and community practices follow a pattern:

• Typical cycle length: 4 to 8 weeks
• Goal-based stopping: Once the target issue has improved, the cycle ends
• Rest period: Some researchers include a break of 2-4 weeks between cycles

BPC-157 doesn’t create dependency or a rebound effect. When you stop, the healing that occurred remains. This makes it fundamentally different from GLP-1 peptides, where the effect reverses after stopping. A tendon that healed stays healed. Gut lining that repaired stays repaired (PMC12313605).

There’s no strong evidence that running BPC-157 indefinitely provides additional benefit beyond the healing period. Once the job is done, you can stop.

Growth Hormone Peptides: Typically Cycled

Peptides like sermorelin, CJC-1295/ipamorelin, and GHRP-2 stimulate your body to produce its own growth hormone. They don’t replace GH — they tell your pituitary gland to make more of it.

The most common approach in research is cycling:

• On period: 12 to 16 weeks
• Off period: 4 to 8 weeks
• Repeat as needed

The reasoning behind cycling is to prevent the pituitary gland from becoming desensitized. If you constantly stimulate GH release, the gland may respond less strongly over time. Taking breaks allows the system to reset.

Sermorelin specifically has a good safety profile in research. It stimulates the body’s natural GH pulsatility rather than flooding the system with external GH, which is why it is generally preferred over direct GH administration in research settings (PMC2699646).

Some researchers use GH peptides continuously at lower doses. The evidence for this approach is less established, but the logic is that a low dose may not trigger desensitization the way a high dose would.

TB-500: 4-6 Week Cycles

TB-500 (thymosin beta-4 fragment) follows a similar pattern to BPC-157. It’s used for targeted healing — tissue repair, wound healing, and reducing inflammation.

• Loading phase: Higher dose for 2-4 weeks
• Maintenance phase: Lower dose for 2-4 additional weeks
• Total cycle: 4-6 weeks typical

Like BPC-157, the effects of TB-500 tend to persist after stopping because the healing itself is the outcome. You’re not masking a symptom — you’re repairing tissue (PMC8228050).

NAD+ Peptides: Ongoing Maintenance

NAD+ (nicotinamide adenine dinucleotide) supplementation is different from most peptide protocols because it addresses a continuous, age-related decline. NAD+ levels naturally decrease as you get older, and supplementation aims to maintain levels rather than fix a specific problem.

Because of this, NAD+ protocols are typically open-ended:

• No fixed cycle length — Ongoing use is the norm
• Dosing may vary — Some researchers use daily protocols, others use periodic treatments
• Stopping is optional — There’s no rebound effect, but NAD+ levels will decline again after stopping

Think of NAD+ more like a daily vitamin than a targeted treatment course.

Cycling vs. Continuous Use: A Summary

Peptide Category	Typical Duration	Approach	What Happens When You Stop
GLP-1 (semaglutide, tirzepatide, retatrutide)	48-104+ weeks	Continuous / long-term	Weight regain (50-75% within one year)
BPC-157	4-8 weeks	Targeted cycles	Healing persists
TB-500	4-6 weeks	Targeted cycles	Healing persists
Sermorelin / GH peptides	12-16 weeks on, 4-8 weeks off	Cycled	GH returns to baseline
NAD+	Ongoing	Continuous maintenance	NAD+ levels decline again
GHK-Cu	8-12 weeks typical	Cycles or continuous	Benefits gradually fade

When to Stop: Three Clear Signals

Regardless of which peptide you’re using, there are three situations where stopping makes sense:

1. You’ve Reached Your Goal

For healing peptides like BPC-157 and TB-500, this is straightforward. The injury healed. The gut is better. The cycle is done. For GLP-1 peptides, reaching your target weight doesn’t necessarily mean stopping — but it may mean transitioning to a lower maintenance dose.

2. Side Effects Outweigh Benefits

Every peptide can cause side effects. If the side effects are persistent and significantly impact quality of life — and adjusting the dose doesn’t help — it’s time to stop and reassess. This is especially relevant for GLP-1 peptides, where GI side effects are common in the early weeks but should improve with time.

3. New Research Changes the Picture

Peptide science moves fast. New studies may reveal long-term effects (positive or negative) that weren’t previously known. Staying informed and adjusting protocols based on new evidence is a mark of responsible research.

The Bottom Line

How long you take a peptide depends entirely on what it does and why you’re taking it. GLP-1 peptides for weight management are a long-term commitment — stopping means regaining the weight. Healing peptides like BPC-157 and TB-500 are short cycles with lasting results. GH peptides are cycled to prevent desensitization. NAD+ is ongoing maintenance.

The worst approach is to use any peptide without a plan. Before starting, know your goal, your timeline, and your exit strategy.

Written by NorthPeptide Research Team

Summary of Key Research References

Topic	Reference	PMC ID
Semaglutide 2-year weight loss (STEP 5)	Two-year effects of semaglutide in adults with overweight or obesity (2022)	PMC9556320
Weight regain after semaglutide withdrawal (STEP 1 extension)	Weight regain and cardiometabolic effects after withdrawal of semaglutide (2022)	PMC9542252
Weight regain meta-analysis across GLP-1 drugs	Rebound or Retention: Meta-Analysis of Weight Regain After GLP-1 RA Discontinuation (2025)	PMC12535773
Weight regain narrative review (liraglutide, semaglutide, tirzepatide)	Weight Regain After Liraglutide, Semaglutide or Tirzepatide Interruption (2025)	PMC12155999
Tirzepatide maintenance (SURMOUNT-4)	Continued Treatment With Tirzepatide for Maintenance of Weight Reduction (2023)	PMC10714284
BPC-157 musculoskeletal systematic review	Emerging Use of BPC-157 in Orthopaedic Sports Medicine (2025)	PMC12313605
Thymosin beta-4 regenerative properties	Utilizing Developmentally Essential Secreted Peptides (2021)	PMC8228050
Sermorelin in adult GH insufficiency	Sermorelin: A better approach to adult-onset GH insufficiency (2005)	PMC2699646

For laboratory and research use only. Not for human consumption.